Clinical Trials
Alkermes begins Phase II trial of ALKS 2680 for narcolepsy type 1
The Vibrance-1 study is designed to assess ALKS 2680’s safety and efficacy in people with NT1.
The Vibrance-1 study is designed to assess ALKS 2680’s safety and efficacy in people with NT1.